Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Joint pain and no interference with activity; Moderate muscle pain with some interference with activity; Mild fever (100.4 to 101.2 °F); Moderate fatigue with some interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache and no interference with activity; Moderate injection site redness; Mild injection site swelling; Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch); This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F)) and FATIGUE (Moderate fatigue with some interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), HEADACHE (Headache and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Moderate fatigue with some interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), HEADACHE (Headache and no interference with activity), VACCINATION SITE ERYTHEMA (Moderate injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100.4 to 101.2 °F, Mild fever..         Concomitant medication was not provided. During the 2 days after COVID-19 vaccination i.e., 02-Jan-2024 and 03-Jan-2024, patient experienced mild injection site pain and no interference with activity, mild injection site tenderness (tender to touch), moderate injection site redness, mild injection site swelling, mild fever, moderate fatigue with some interference with activity, mild malaise/feeling sick and no interference with activity, moderate muscle pain with some interference with activity, Joint pain and no interference with activity, mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting and headache and no interference with activity. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971: